Amneal Pharmaceuticals logo
Amneal Pharmaceuticals AMRX
$ 13.47 -2.46%

Annual report 2025
added 02-27-2026

report update icon

Amneal Pharmaceuticals Income Statement 2011-2026 | AMRX

Annual Income Statement Amneal Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.31 B 1.83 B 1.04 B 290 M 660 M 709 M 613 M 1.52 B - - - - - - -

Shares

313 M 309 M 176 M 151 M 149 M 147 M 132 M 127 M - - - - - - -

Historical Prices

13.8 5.91 5.91 1.92 4.43 4.81 4.49 12.3 - - - - - - -

Net Income

72.1 M -117 M -84 M -255 M 13.2 M 67.8 M -362 M -170 M 168 M 207 M - - - - -

Revenue

3.02 B 2.79 B 2.39 B 2.21 B 2.09 B 1.99 B 1.63 B 1.66 B 1.03 B 1.02 B - - - - -

Cost of Revenue

1.91 B 1.77 B 1.57 B 1.43 B 1.32 B 1.33 B 1.15 B 939 M 507 M 421 M - - - - -

Gross Profit

1.11 B 1.02 B 821 M 785 M 769 M 628 M 353 M 716 M 526 M 597 M - - - - -

Operating Income

394 M 249 M 204 M -94.9 M 153 M 91.2 M -249 M -19.7 M 245 M 285 M - - - - -

Interest Expense

16.5 M 11.8 M 8.24 M 18.5 M 15.3 M 2.59 M 1.46 M 1.18 M -47 K -669 K - - - - -

EBITDA

451 M 312 M 271 M -26.8 M 213 M 152 M 21.7 M 374 M 271 M 307 M - - - - -

Operating Expenses

- - - - - - 539 M 480 M 301 M 324 M - - - - -

General and Administrative Expenses

527 M 476 M 430 M 400 M 366 M 327 M 290 M 230 M 109 M 119 M - - - - -

All numbers in USD currency

Quarterly Income Statement Amneal Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

314 M 314 M 311 M 310 M 309 M 307 M 154 M 154 M 152 M - 151 M 151 M 150 M - 149 M 149 M 148 M - 148 M 147 M 147 M - 131 M 128 M 128 M - 127 M 127 M 1 K 1 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

2.37 M 22.4 M 12.2 M -156 K 5.99 M -91.6 M 9.68 M 11.9 M -6.94 M - -7.61 M -242 M -8.82 M - -7.78 M 30 M 12.7 M - -21.6 M -24.2 M 120 M -64.9 M -265 M -16.9 M -47.9 M -20.3 M 6.89 M -17.9 M - - - - 42.3 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

785 M 725 M 695 M 702 M 702 M 659 M 620 M 599 M 558 M - 546 M 559 M 498 M - 529 M 535 M 493 M - 519 M 465 M 499 M 397 M 378 M 405 M 446 M 498 M 476 M 414 M - - 255 M 260 M 226 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

511 M 438 M 440 M 433 M 452 M 421 M 388 M 379 M 379 M - 351 M 359 M 323 M - 329 M 323 M 302 M - 353 M 320 M 314 M - 268 M 296 M 310 M - 269 M 235 M 131 M - 120 M 136 M - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

274 M 286 M 256 M 270 M 250 M 238 M 233 M 220 M 178 M - 194 M 201 M 175 M - 199 M 212 M 192 M - 134 M 144 M 183 M 110 M 54.4 M 105 M 83.1 M 193 M 200 M 178 M 145 M 151 M 135 M 124 M 116 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

70.3 M 111 M 100 M 88.8 M 95.5 M -10.7 M 75.6 M 80.1 M 34.4 M - 44.4 M -199 M 23.3 M - 28.5 M 67.1 M 45.9 M - 2.44 M 10.8 M 57.8 M - -112 M -18.9 M -94.4 M - 74.6 M -181 M 63.6 M - 78.8 M 44.6 M - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

1.24 M 1.6 M 518 K 1.18 M 4.36 M 4.07 M 1.83 M 417 K 4.36 M - 5.71 M 6.94 M 2.12 M - 3.87 M 4.03 M 794 K - 898 K 571 K 633 K - 446 K 149 K 1.11 M - -1.01 M 791 K 948 K - -93 K -78 K - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

110 M 157 M 146 M 132 M 136 M 29.2 M 116 M 121 M 75.5 M - 88.9 M -157 M 64.2 M - 72.3 M 111 M 87.6 M - 47 M 54.7 M 100 M - -74.3 M 15.9 M -63.4 M - 91.9 M -166 M 65.3 M - 89.4 M 54.3 M - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

138 M 124 M 118 M 119 M 116 M 113 M 113 M 106 M 102 M - 100 M 98.8 M 98.7 M - 91.4 M 86.2 M 90.7 M - 83.1 M 80.9 M 78 M - 63.8 M 67.3 M 84.4 M - 75.5 M 56 M 25.1 M - 27.4 M 26.9 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Amneal Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.11 -13.17 % $ 217 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 163.89 - $ 8.15 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 64.28 -3.31 % $ 12.3 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BioCardia BioCardia
BCDA
$ 1.37 5.81 % $ 29 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.82 -0.35 % $ 908 M israelIsrael
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 59.8 -3.13 % $ 11.5 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.08 -0.46 % $ 126 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.93 0.23 % $ 450 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 109.33 -0.82 % $ 27.2 B germanyGermany
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 2.38 -3.44 % $ 131 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.63 -2.4 % $ 4.13 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Burford Capital Limited Burford Capital Limited
BUR
$ 8.65 2.49 % $ 1.39 B britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
BeyondSpring BeyondSpring
BYSI
$ 1.34 -0.87 % $ 54 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.34 0.61 % $ 3.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.88 2.74 % $ 10.6 B israelIsrael
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 27.28 -2.32 % $ 731 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.67 -3.47 % $ 768 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.06 13.3 % $ 254 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Codexis Codexis
CDXS
$ 0.99 -2.04 % $ 72.7 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA